News

By continuing to explore potential treatments with different targets, as opposed to focusing exclusively on beta-amyloid proteins, researchers stand a better chance to find effective treatments for Alzheimer’s. As the Alzheimer’s Association claims on their website, “The first survivor of Alzheimer’s is out there.”

With a global societal cost of over $1 trillion annually, Alzheimer’s is one of the world’s most expensive diseases. Put another way, if Alzheimer’s were a corporation, its costs would be more than the combined profit of the 10 largest corporations in the US today.